Manufacturers report positive results for long term efficacy of siponimod for secondary progressive multiple sclerosis

In the five-year EXPAND open-label extension trial patients on siponimod were significantly less likely to experience both three- and six-month confirmed disability progression compared vs the placebo switch group, and they had a 52% reduction in the annualised relapse rate.